These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lecanemab: Looking Before We Leap. Burke JF; Kerber KA; Langa KM; Albin RL; Kotagal V Neurology; 2023 Oct; 101(15):661-665. PubMed ID: 37479527 [TBL] [Abstract][Full Text] [Related]
3. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review. Chowdhury S; Chowdhury NS Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139 [TBL] [Abstract][Full Text] [Related]
4. Profiling lecanemab as a treatment option for Alzheimer's disease. Schiller ER; Silverglate BD; Grossberg GT Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584 [TBL] [Abstract][Full Text] [Related]
5. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review. Hossain MF; Husna AU; Kharel M Brain Behav; 2024 Jun; 14(6):e3592. PubMed ID: 38867460 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446 [TBL] [Abstract][Full Text] [Related]
7. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease. Kurkinen M Adv Clin Exp Med; 2023 Sep; 32(9):943-947. PubMed ID: 37676096 [TBL] [Abstract][Full Text] [Related]
8. Lecanemab: More Questions Than Answers! Kaur U; Reddy J; Tiwari A; Chakrabarti S; Chakrabarti SS Clin Drug Investig; 2024 Jan; 44(1):1-10. PubMed ID: 38095822 [TBL] [Abstract][Full Text] [Related]
9. Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials. Wolters FJ; Labrecque JA Alzheimers Dement; 2024 Apr; 20(4):3119-3125. PubMed ID: 38380503 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. Abdelazim K; Allam AA; Afifi B; Abdulazeem H; Elbehiry AI Neurol Sci; 2024 Aug; 45(8):3583-3597. PubMed ID: 38565747 [TBL] [Abstract][Full Text] [Related]
12. Passive Alzheimer's immunotherapy: A promising or uncertain option? Høilund-Carlsen PF; Revheim ME; Costa T; Alavi A; Kepp KP; Sensi SL; Perry G; Robakis NK; Barrio JR; Vissel B Ageing Res Rev; 2023 Sep; 90():101996. PubMed ID: 37414156 [TBL] [Abstract][Full Text] [Related]
13. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift? Knopman DS; Hershey L Neurology; 2023 Oct; 101(14):610-620. PubMed ID: 37295957 [TBL] [Abstract][Full Text] [Related]
14. Lecanemab in Early Alzheimer's Disease. van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413 [TBL] [Abstract][Full Text] [Related]
15. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. Ebell MH; Barry HC; Baduni K; Grasso G Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509 [TBL] [Abstract][Full Text] [Related]
16. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. McDade E; Cummings JL; Dhadda S; Swanson CJ; Reyderman L; Kanekiyo M; Koyama A; Irizarry M; Kramer LD; Bateman RJ Alzheimers Res Ther; 2022 Dec; 14(1):191. PubMed ID: 36544184 [TBL] [Abstract][Full Text] [Related]
17. Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers? Høilund-Carlsen PF; Alavi A; Castellani RJ; Neve RL; Perry G; Revheim ME; Barrio JR Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612701 [TBL] [Abstract][Full Text] [Related]
18. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective. Volloch V; Rits-Volloch S J Alzheimers Dis; 2023; 93(4):1277-1284. PubMed ID: 37212119 [TBL] [Abstract][Full Text] [Related]
19. Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. Cohen S; van Dyck CH; Gee M; Doherty T; Kanekiyo M; Dhadda S; Li D; Hersch S; Irizarry M; Kramer LD J Prev Alzheimers Dis; 2023; 10(4):771-777. PubMed ID: 37874099 [TBL] [Abstract][Full Text] [Related]
20. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Vitek GE; Decourt B; Sabbagh MN Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]